Dawn Peck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dawn Peck has a total of 275 co-authors. Here are the top co-authors by number of shared publications:
Amanda J. Moffitt
Department of Human Development and Family Studies, University of Missouri, Columbia, MO, United States
6 shared publications- Shawn E. Christ
University of Missouri
5 shared publications - Desiree A. White
Department of Psychology, Campus Box 1125, Washington University, St. Louis, MO 63130, USA
4 shared publications - Amy L. White
Biochemical Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
3 shared publications - Devin Oglesbee
Biochemical Genetics Laboratory, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
3 shared publications Shawn E. Christ
3 shared publications
Latest Publications
- Open Access
- 2 August 2026
- Published by Elsevier in SSRN Electronic Journal
Pseudodeficiency: A Poorly Defined and Misunderstood Term in an Era of Precision Medicine
Historically, the term “pseudodeficiency” has referred to individuals with significantly reduced activity of a specific enzyme in vitro but lacking phenotypic evidence of the associated disease. This phenomenon complicates the interpretation of enzyme activity-based laboratory testing, an issue that has become increasingly problematic with the expansion of newborn screening panels to include biochemical genetic conditions like lysosomal diseases that use measurement of enzyme activity as a first tier. While the term “pseudodeficiency” has been broadly used for over 40 years, it remains ill-defined and this has led to confusion. To better understand pseudodeficiency, and to create a platform for future work, we carried out a literature review. We identified 63 variants in 12 genes that have been reported as a probable or possible cause of pseudodeficiency. These variants have been demonstrated to result in enzyme deficiency through mechanisms such as altered gene expression, altered enzyme stability, or altered trafficking. As such, the term “pseudo”, which implies that the laboratory measurement was “false”, or artifactual, is misleading as many of these variants have been demonstrated to lead to measurable reduction of enzyme activity in vitro. Furthermore, evidence indicates that, when in cis with another missense variant, these variants can act synergistically to further lower enzyme activity. The implementation of systematized variant curation raises the risk of these pseudodeficiency variants being classified as “benign”, which could result in relevant variants being filtered by bioinformatic pipelines. We propose that further work is needed to better define “pseudodeficiency”, to generate an accepted nomenclature and framework to classify and report these variants, and to investigate whether these variants have any role in multifactorial disease.
- 2 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessPseudodeficiency: A Poorly Defined and Misunderstood Term in an Era of Precision Medicine
Historically, the term “pseudodeficiency” has referred to individuals with significantly reduced activity of a specific enzyme in vitro but lacking phenotypic evidence of the associated disease. This phenomenon complicates the interpretation of enzyme activity-based laboratory testing, an issue that has become increasingly problematic with the expansion of newborn screening panels to include biochemical genetic conditions like lysosomal diseases that use measurement of enzyme activity as a first tier. While the term “pseudodeficiency” has been broadly used for over 40 years, it remains ill-defined and this has led to confusion. To better understand pseudodeficiency, and to create a platform for future work, we carried out a literature review. We identified 63 variants in 12 genes that have been reported as a probable or possible cause of pseudodeficiency. These variants have been demonstrated to result in enzyme deficiency through mechanisms such as altered gene expression, altered enzyme stability, or altered trafficking. As such, the term “pseudo”, which implies that the laboratory measurement was “false”, or artifactual, is misleading as many of these variants have been demonstrated to lead to measurable reduction of enzyme activity in vitro. Furthermore, evidence indicates that, when in cis with another missense variant, these variants can act synergistically to further lower enzyme activity. The implementation of systematized variant curation raises the risk of these pseudodeficiency variants being classified as “benign”, which could result in relevant variants being filtered by bioinformatic pipelines. We propose that further work is needed to better define “pseudodeficiency”, to generate an accepted nomenclature and framework to classify and report these variants, and to investigate whether these variants have any role in multifactorial disease.
- 3 February 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 135 (2) , S71
Initial symptom presentation in young pediatric patients with classic pathogenic variants in the gene: Data from the Fabry MOPPet study
- 3 February 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 135 (2) , S71
Initial symptom presentation in young pediatric patients with classic pathogenic variants in the gene: Data from the Fabry MOPPet study
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S2-S3
How does plasma oxysterols analysis compare to fibroblast filipin staining for diagnosis of Niemann-Pick C disease?
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S2-S3
How does plasma oxysterols analysis compare to fibroblast filipin staining for diagnosis of Niemann-Pick C disease?
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S29-S30
Comparison of psychosine analysis in dried blood spots and red blood cells in Krabbe disease
- 9 April 2021
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 132, S29-S30
Comparison of psychosine analysis in dried blood spots and red blood cells in Krabbe disease
- 1 October 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 292, 91-94
Surgical septal myectomy for relief of dynamic obstruction in Anderson-Fabry Disease
- 1 October 2019
- Published by Elsevier in International Journal of Cardiology
- Vol. 292, 91-94
Surgical septal myectomy for relief of dynamic obstruction in Anderson-Fabry Disease
- 1 January 2019
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (1) , 84-88
Cost Efficacy of α-Galactosidase A Enzyme Screening for Fabry Disease
- 1 January 2019
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 94 (1) , 84-88
Cost Efficacy of α-Galactosidase A Enzyme Screening for Fabry Disease
- Open Access
- 13 August 2018
- Published by Oxford University Press (OUP) in Brain
- Vol. 141 (9) , 2576-2591
SYT1-associated neurodevelopmental disorder: a case series
Synaptotagmin 1 (SYT1) is a critical mediator of fast, synchronous, calcium-dependent neurotransmitter release and also modulates synaptic vesicle endocytosis. This paper describes 11 patients with de novo heterozygous missense mutations in SYT1. All mutations alter highly conserved residues, and cluster in two regions of the SYT1 C2B domain at positions Met303 (M303K), Asp304 (D304G), Asp366 (D366E), Ile368 (I368T) and Asn371 (N371K). Phenotypic features include infantile hypotonia, congenital ophthalmic abnormalities, childhood-onset hyperkinetic movement disorders, motor stereotypies, and developmental delay varying in severity from moderate to profound. Behavioural characteristics include sleep disturbance and episodic agitation. Absence of epileptic seizures and normal orbitofrontal head circumference are important negative features. Structural MRI is unremarkable but EEG disturbance is universal, characterized by intermittent low frequency high amplitude oscillations. The functional impact of these five de novo SYT1 mutations has been assessed by expressing rat SYT1 protein containing the equivalent human variants in wild-type mouse primary hippocampal cultures. All mutant forms of SYT1 were expressed at levels approximately equal to endogenous wild-type protein, and correctly localized to nerve terminals at rest, except for SYT1M303K, which was expressed at a lower level and failed to localize at nerve terminals. Following stimulation, SYT1I368T and SYT1N371K relocalized to nerve terminals at least as efficiently as wild-type SYT1. However, SYT1D304G and SYT1D366E failed to relocalize to nerve terminals following stimulation, indicative of impairments in endocytic retrieval and trafficking of SYT1. In addition, the presence of SYT1 variants at nerve terminals induced a slowing of exocytic rate following sustained action potential stimulation. The extent of disturbance to synaptic vesicle kinetics is mirrored by the severity of the affected individuals’ phenotypes, suggesting that the efficiency of SYT1-mediated neurotransmitter release is critical to cognitive development. In summary, de novo dominant SYT1 missense mutations are associated with a recognizable neurodevelopmental syndrome, and further cases can now be diagnosed based on clinical features, electrophysiological signature and mutation characteristics. Variation in phenotype severity may reflect mutation-specific impact on the diverse physiological functions of SYT1.
- 13 August 2018
- Published by Oxford University Press (OUP) in Brain
- Vol. 141 (9) , 2576-2591
Open AccessSYT1-associated neurodevelopmental disorder: a case series
Synaptotagmin 1 (SYT1) is a critical mediator of fast, synchronous, calcium-dependent neurotransmitter release and also modulates synaptic vesicle endocytosis. This paper describes 11 patients with de novo heterozygous missense mutations in SYT1. All mutations alter highly conserved residues, and cluster in two regions of the SYT1 C2B domain at positions Met303 (M303K), Asp304 (D304G), Asp366 (D366E), Ile368 (I368T) and Asn371 (N371K). Phenotypic features include infantile hypotonia, congenital ophthalmic abnormalities, childhood-onset hyperkinetic movement disorders, motor stereotypies, and developmental delay varying in severity from moderate to profound. Behavioural characteristics include sleep disturbance and episodic agitation. Absence of epileptic seizures and normal orbitofrontal head circumference are important negative features. Structural MRI is unremarkable but EEG disturbance is universal, characterized by intermittent low frequency high amplitude oscillations. The functional impact of these five de novo SYT1 mutations has been assessed by expressing rat SYT1 protein containing the equivalent human variants in wild-type mouse primary hippocampal cultures. All mutant forms of SYT1 were expressed at levels approximately equal to endogenous wild-type protein, and correctly localized to nerve terminals at rest, except for SYT1M303K, which was expressed at a lower level and failed to localize at nerve terminals. Following stimulation, SYT1I368T and SYT1N371K relocalized to nerve terminals at least as efficiently as wild-type SYT1. However, SYT1D304G and SYT1D366E failed to relocalize to nerve terminals following stimulation, indicative of impairments in endocytic retrieval and trafficking of SYT1. In addition, the presence of SYT1 variants at nerve terminals induced a slowing of exocytic rate following sustained action potential stimulation. The extent of disturbance to synaptic vesicle kinetics is mirrored by the severity of the affected individuals’ phenotypes, suggesting that the efficiency of SYT1-mediated neurotransmitter release is critical to cognitive development. In summary, de novo dominant SYT1 missense mutations are associated with a recognizable neurodevelopmental syndrome, and further cases can now be diagnosed based on clinical features, electrophysiological signature and mutation characteristics. Variation in phenotype severity may reflect mutation-specific impact on the diverse physiological functions of SYT1.
- Open Access
- 1 August 2018
- Published by Elsevier in Genetics in Medicine
- Vol. 20 (8) , 847-854
Precision newborn screening for lysosomal disorders
- 1 August 2018
- Published by Elsevier in Genetics in Medicine
- Vol. 20 (8) , 847-854
Open AccessPrecision newborn screening for lysosomal disorders
- Open Access
- 1 September 2016
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 8, 85-86
Response to letter to the editor: Why does Leigh syndrome responds to immunotherapy?
- 1 September 2016
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 8, 85-86
Open AccessResponse to letter to the editor: Why does Leigh syndrome responds to immunotherapy?
- Open Access
- 1 September 2016
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 119 (1-2) , 75-82
221 newborn-screened neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency: Findings from the Inborn Errors of Metabolism Collaborative
- 1 September 2016
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 119 (1-2) , 75-82
Open Access221 newborn-screened neonates with medium-chain acyl-coenzyme A dehydrogenase deficiency: Findings from the Inborn Errors of Metabolism Collaborative